INTRODUCTION
Eosinophilic gastrointestinal disorders (EGID) are chronic allergen/immune-mediated disorders characterized by eosinophilic inflammation in the gastrointestinal (GI) tract and symptoms referable to the site of GI tract involvement. Eosinophilic gastrointestinal disorders include eosinophilic esophagitis (EoE), gastritis (EG), DOI: http://dx.doi.org/10.15403/jgld.2014.1121.281.syd gastroenteritis (EGE), and colitis (EC). Although EGID are thought to be allergen-mediated, studies have also linked EGID with connective tissue disorders [1] and other autoimmune disorders [2] . Similarly, postural orthostatic tachycardia syndrome (POTS) has been linked to connective tissue disorders and autoimmune diseases, but the association between EGID and POTS, as well as other conditions of autonomic dysfunction, has not been extensively described.
POTS belongs to a group of disorders under the term autonomic dysfunction, pathology that stem from dysregulation and dysfunction of the autonomic nervous system. POTS is characterized by an excessive increase in heart rate in the absence of orthostatic hypotension and that is not explained by medications or other causes of tachycardia [3] . Diagnosis is established with: 1) an increase of 30 bpm within 10 minutes of tilt table testing; 2) lack of hypotension, which is defined as a decrease in systolic BP >20mmHg or diastolic BP >10mmHg; and 3) associated symptoms such as lightheadedness, palpitations, vision changes, and generalized weakness. Treatments include physical conditioning, increased fluid/ salt intake, and medicines such as propranolol, midodrine, fludrocortisone, and pyridostigmine. POTS is a final common pathway for many diseases and has been associated with Ehlers-Danlos syndrome (EDS), mast cell activation syndrome (MCAS), chronic fatigue syndrome, and autoimmune disorders [3, 4] . Gastroparesis is another common form of autonomic dysfunction. Gastroparesis stems from dysfunctional GI motility, resulting in gastric stasis, delayed gastric emptying, and symptoms of nausea, vomiting, and abdominal pain.
ORIGINAL PAPER
Gastrointestinal symptoms and impaired gastric motility are prevalent in up to 69% of patients with POTS [5] , and gastroparesis is a common culprit given the shared pathophysiology between POTS and gastroparesis. However, patients with POTS and GI symptoms have also been shown to have a higher prevalence of comorbid irritable bowel syndrome (IBS) and inflammatory bowel diseases (IBD) [6] , as well as other functional GI disorders [5] . Coexisting EGID could be another explanation for GI symptoms in POTS, and we have clinically observed an association. However, this association has not been extensively described. Therefore, our aims were to identify patients with EGID and POTS, describe the association between these two entities, and assess the prevalence of autonomic dysfunction in our EGID population.
METHODS
This was a retrospective cohort study conducted at the University of North Carolina (UNC). We identified adult patients (>18 years old) in the EoE/EGID database at UNC who also had a diagnosis of comorbid autonomic dysfunction (POTS or gastroparesis). The details of this database have been previously described [7] [8] [9] [10] [11] [12] . In brief, pathology records and billing codes are routinely monitored to identify all patients with EGID diagnosis. Eosinophilic esophagitis was defined as per consensus guidelines [13, 14] . As there are no consensus guidelines for EG, EGE, or EC, these have been defined as per recent recommendations for histologic thresholds for GI eosinophilia, in the presence of appropriate symptoms, and in the absence of competing secondary causes of eosinophilia [15] . Within this EoE/EGID database, we screened for cases of comorbid autonomic dysfunction (POTS and gastroparesis) via record review. Cases were then verified by identifying documentation of positive tilt-table testing and gastric emptying studies for POTS and gastroparesis, respectively.
Once all cases were identified, the electronic medical record was abstracted using a standardized case report form for data regarding their EGID and POTS, including demographic information, disease characteristics and diagnostic information, treatments, and presence of other comorbidities.
For analysis, we used descriptive statistics (proportions, means) to summarize characteristics of the study population.
We calculated the prevalence of autonomic dysfunction in EGID patients at UNC. This study was approved by the UNC IRB.
RESULTS
We identified 7 patients who had EGID and autonomic dysfunction. All had POTS, all were Caucasian, and 5 were female. There were 4 patients with EoE alone, 2 with EGE and overlapping esophageal involvement, and 1 with EGE overlapping with EC. In addition to POTS, 2 patients also had gastroparesis (Table I ). The median age (in years) at diagnosis of EGID was 28, ranging from 16 to 54. POTS symptoms, from most to least common, included presyncope, palpitations, lightheadedness, dizziness, dyspnea, true syncope, diaphoresis, "black out vision", and "brain fog" (Table II) . Of the six patients with esophageal involvement (with EoE alone or with another overlapping EGID), the most common symptoms were dysphagia and epigastric abdominal pain, followed by heartburn, nausea and vomiting. Of the three patients with EGE, the most common symptoms were nausea and vomiting and abdominal pain (Table III) .
Onset of POTS symptoms coincided with onset of EGID symptoms in 3 patients or with an acute EGID flare in 3 patients. Other potential triggers of autonomic symptoms included pregnancy in two patients and transition to college in one patient. For POTS, 6 of the patients sought treatment with an autonomic dysfunction specialist. The most common treatments included liberalized fluid and salt intake, physical conditioning, corticosteroids (hydrocortisone, fludrocortisone) and pyridostigmine (Table II) . Oral viscous budesonide, swallowed fluticasone, targeted dietary elimination, elemental diet, and/or endoscopic dilations were sufficient to control disease activity in the four patients with only EoE. The three patients with EGE (overlapping with either esophageal involvement or EC) required systemic steroids to control their EGID (Table III) . In no case did the successful control of EGID lead to the improvement of autonomic symptoms. Median follow up time after EGID remission was 4 years, and ranged from 1 to 8 years.
Two patients had comorbid EDS and two patients MCAS. One patient had both EDS and MCAS. Three patients had hypothyroidism (one of whom was documented as Hashimoto's), and one had celiac disease (Table I) . None of the patients studied had comorbid diabetes mellitus.
Using the UNC EoE/EGID database (n=560 adults at the time this study was performed), we calculated a prevalence of POTS in EGID patients as 7/560 (1.25%), compared to the estimated previously published 0.17% prevalence of POTS in the general population [3, 16] .
DISCUSSION
Given the inflammatory involvement of the GI tract in EGID, the variable symptoms associated with these conditions, and the fact that eosinophils can impact both motility and nerve function, it is plausible that there is an association between EGID and autonomic dysfunction. We had anecdotally observed this association during routine clinical care, but this has not been extensively evaluated in the medical literature. Our data suggest that POTS is perhaps 5-10 fold more prevalent in patients with EGID than in the general population. Moreover, onset of POTS tended to coincide with onset/flares of EGID in our patients, potentially suggesting a pathogenic association between EGID and POTS. Although two of the patients in our cohort also had gastroparesis, it remains unclear whether EGID is associated with other forms of autonomic dysfunction.
Given this possible association, we tried to identify distinguishing features of our patients' EGID and POTS compared to typical presentations. Patients all had typical presentations of EGID, with EoE predominantly presenting with dysphagia, and EGE causing mostly abdominal pain, nausea and vomiting. Similarly, the most common POTS symptoms (palpitations, lightheadedness, dizziness, and dyspnea) were all observed in most of our patients. Interestingly, the demographics of this subset of patients showed a strong female predominance. Although this is consistent with non-EoE EGIDs as well as with POTS [3] , EoE has a male predominance, and the majority (4/7) of our patients had EoE alone [17] .
Underlying mechanisms for the association between EGID and POTS remain unclear. One possible mechanism involves the underlying inflammation in EGID directly modulating the autonomic nervous system and causing symptoms of autonomic dysfunction. Many allergy disorders manifest with symptoms that are mediated by changes in the nervous system, and mechanisms of allergen-induced neuromodulation have been previously described [18] . Previous studies have demonstrated that mast cells and eosinophils can act as neuroactive mediators at sites of allergic inflammation, sensitizing the nervous system response to antigens. This has [19] . The study suggests that inflammation in the esophagus similar to that found in EoE leads to formation of neurotrophic factors that upregulate transcription of TRPV1 in neurons, thereby modulating the function of the nervous system and in particular causing visceral hypersensitivity. As this was a retrospective study and biopsies were clinically taken only of the mucosa, we were not able to evaluation eosinophil and nerve interactions. Further research is required to determine if a similar pathway is present in humans, and if a form of allergen-induced neuromodulation could underlye a mechanism in which EGID could lead to autonomic symptoms such as those in POTS. Additional investigations would also be required to understand if fibrosis related to EGE could impact on gastric function and lead to gastroparesis. Another possibility is that a separate distinct process could be underlying or leading to the development of both EGID and POTS. Within our cohort, we identified EDS and MCAS as possibilities. Ehlers Danlos syndrome, seen in two of our patients, is a connective tissue disorder (CTD) that has an association with POTS that has been well established [20] [21] [22] . Recent studies have demonstrated a higher prevalence of EoE among patients with CTD such as EDS [1] , and have shown that dysregulation in transforming growth factor beta (TGF-β) levels and subsequent errors in signaling can underly the pathogenesis of both EGID and CTD [23] . TGF-β may also mediate dysmotility in the esophagus, though it is unknown if this may be at play throughout the rest of the GI tract. Similarly observed in two of our patients, MCAS has been shown to be associated with hyperadrenergic POTS [24] . Abnormal mast cell release of vasoactive mediators lead to vasodilation and subsequent orthostatic intolerance. Mast cells are implicated in the pathophysiology of immune/allergy mediated disorders such as EGID, and MCAS has been linked to atopic diseases such as asthma and allergic rhinitis, with which EGID is also linked. Moreover, studies have demonstrated that some patients with EoE have elevated tryptase levels indicative of increased mast cell activation [25] . Ehlers Danlos syndrome and MCAS have been linked as well [26] , raising the possibility of a unifying mechanism underlying all four syndromes (EGID, POTS, EDS, and MCAS).
An autoimmune etiology could also connect both EGID and POTS. Eosinophilic esophagitis has been associated with other autoimmune conditions such as Hashimoto's (as seen in our cohort), multiple sclerosis, and lupus [27] . POTS has been linked also with autoimmune disorders [4, 28, 29] .
Alternatively, our study population could represent a coincidental overlap of symptoms, and such a small sample size is insufficiently powered to conduct a statistical analysis. Our study is also limited by its retrospective design, with data obtained from a chart review. Notably, we were unable to discern the POTS subtypes (i.e. neuropathic POTS, hyperadrenergic POTS, etc.) from a chart review alone. However, these limitations are countered by the large patient population assessed with comprehensive case finding strategies and standardized extraction of data.
CONCLUSIONS
Our data suggests that POTS is 5-10 fold more prevalent in patients with EGID than in the general population, and that EGID may be associated with POTS and gastroparesis. Patients with EGID and POTS tended to be female, but otherwise presented with typical symptoms of both disorders. POTS symptoms persisted in our patients despite EGID treatments. Although further research examining other cohorts is required to determine if this is a true association, providers should consider comorbid autonomic dysfunction in patients with EGID. Because our data suggests that autonomic symptoms are likely to persist despite treatment of EGID, providers should consider referral to an autonomic specialist for treatment of these symptoms even if EGID itself is well controlled.
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